{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:42:26Z","timestamp":1791499346065,"version":"4.3.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"13","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Ada and Hagbart Waages Humanit\u00e6re og Veldedige Stiftelse"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>This study aims to investigate if elevated levels of cholesterol carried in triglyceride-rich lipoproteins, marked by remnant cholesterol or plasma triglycerides, are associated with increased risk of premature cardiovascular disease (CVD) events in young adults.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>This study is a prospective cohort study. In the year 2000, all 30-year-old inhabitants living in Oslo, Norway, were invited to the \u2018Oslo Health Study\u2019 including a clinical examination and routine blood tests. Follow-up with respect to CVD events (cardiovascular death, non-fatal myocardial infarction, non-fatal ischaemic stroke, coronary revascularization, or hospitalization for unstable angina) was obtained by linkage with national mandatory registries through 2022. We estimated the risk of CVD events in relation to levels of remnant cholesterol and plasma triglycerides at inclusion using Cox regression analysis. The risk of CVD events in relation to LDL cholesterol (LDL-C) levels was estimated as comparison. A total of 5939 participants were included (median age 31 years, 56% women). During a median follow-up time of 22 years, a CVD event occurred in 107 (1.8%) participants. The adjusted hazard ratio (aHR) for CVD events per 0.5\u2005mmol\/L increase in remnant cholesterol concentrations was 1.3 [95% confidence interval (CI): 1.1\u20131.5]. Per 1\u2005mmol increase in plasma triglycerides and LDL-C concentrations, the aHR for CVD events was 1.2 (95% CI: 1.1\u20131.4) and 1.3 (95% CI: 1.1\u20131.6), respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Already at 31 years of age, higher concentrations of remnant cholesterol and plasma triglycerides were associated with increased risk of premature CVD events. We suggest that remnant cholesterol or plasma triglycerides are included in the risk assessment of young adults.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwaf104","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T08:47:23Z","timestamp":1740473243000},"page":"1181-1189","source":"Crossref","is-referenced-by-count":27,"title":["Remnant cholesterol, plasma triglycerides, and risk of cardiovascular disease events in young adults: a prospective cohort study"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3449-0407","authenticated-orcid":false,"given":"Eirik","family":"Aaseth","sequence":"first","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Ulleval and Institute of Clinical Medicine, University of Oslo , Pb 4950 Nydalen, 0424 Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Halvorsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Ulleval and Institute of Clinical Medicine, University of Oslo , Pb 4950 Nydalen, 0424 Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragnhild","family":"Helseth","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Ulleval and Institute of Clinical Medicine, University of Oslo , Pb 4950 Nydalen, 0424 Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Gravning","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Ulleval and Institute of Clinical Medicine, University of Oslo , Pb 4950 Nydalen, 0424 Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"2025092119523427300_zwaf104-B1","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics-2023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"2025092119523427300_zwaf104-B2","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.jacc.2023.09.817","article-title":"Primary prevention of subclinical atherosclerosis in young adults: JACC review topic of the week","volume":"82","author":"Devesa","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025092119523427300_zwaf104-B3","doi-asserted-by":"crossref","first-page":"e016115","DOI":"10.1161\/JAHA.120.016115","article-title":"Challenges and opportunities for the prevention and treatment of cardiovascular disease among young adults: report from a national heart, lung, and blood institute working group","volume":"9","author":"Gooding","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025092119523427300_zwaf104-B4","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nrcardio.2017.154","article-title":"Epidemiology of cardiovascular disease in young individuals","volume":"15","author":"Andersson","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2025092119523427300_zwaf104-B5","doi-asserted-by":"crossref","first-page":"e011433","DOI":"10.1161\/JAHA.118.011433","article-title":"Trajectories of blood lipid concentrations over the adult life course and risk of cardiovascular disease and all-cause mortality: observations from the Framingham Study over 35 years","volume":"8","author":"Duncan","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2025092119523427300_zwaf104-B6","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time course of LDL cholesterol exposure and cardiovascular disease event risk","volume":"76","author":"Domanski","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025092119523427300_zwaf104-B7","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"2025092119523427300_zwaf104-B8","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.jacc.2020.10.008","article-title":"Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease","volume":"76","author":"Castaner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025092119523427300_zwaf104-B9","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1093\/eurheartj\/ehab432","article-title":"Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study","volume":"42","author":"Quispe","year":"2021","journal-title":"Eur Heart J"},{"key":"2025092119523427300_zwaf104-B10","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1373\/clinchem.2015.253757","article-title":"Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease","volume":"62","author":"Jepsen","year":"2016","journal-title":"Clin Chem"},{"key":"2025092119523427300_zwaf104-B11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1475-9276-3-3","article-title":"The Oslo health study: the impact of self-selection in a large, population-based survey","volume":"3","author":"Sogaard","year":"2004","journal-title":"Int J Equity Health"},{"key":"2025092119523427300_zwaf104-B12","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jamacardio.2020.0013","article-title":"A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and\/or hypertriglyceridemia","volume":"5","author":"Sampson","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2025092119523427300_zwaf104-B13","doi-asserted-by":"crossref","first-page":"100148","DOI":"10.1016\/j.jlr.2021.100148","article-title":"LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials","volume":"63","author":"Ginsberg","year":"2022","journal-title":"J Lipid Res"},{"key":"2025092119523427300_zwaf104-B14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/1403494819859737","article-title":"The Norwegian Patient Registry and the Norwegian Registry for Primary Health Care: research potential of two nationwide health-care registries","volume":"48","author":"Bakken","year":"2020","journal-title":"Scand J Public Health"},{"key":"2025092119523427300_zwaf104-B15","doi-asserted-by":"crossref","first-page":"768","DOI":"10.4045\/tidsskr.14.1065","article-title":"Data quality in the causes of death registry","volume":"135","author":"Pedersen","year":"2015","journal-title":"Tidsskr Nor Laegeforen"},{"key":"2025092119523427300_zwaf104-B16","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1056\/NEJMoa1607991","article-title":"Drug-eluting or bare-metal stents for coronary artery disease","volume":"375","author":"Bonaa","year":"2016","journal-title":"N Engl J Med"},{"key":"2025092119523427300_zwaf104-B17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1403494818803256","article-title":"Completeness and correctness of acute myocardial infarction diagnoses in a medical quality register and an administrative health register","volume":"48","author":"Govatsmark","year":"2020","journal-title":"Scand J Public Health"},{"key":"2025092119523427300_zwaf104-B18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1403494815621641","article-title":"Comparison of the validity of stroke diagnoses in a medical quality register and an administrative health register","volume":"44","author":"Varmdal","year":"2016","journal-title":"Scand J Public Health"},{"key":"2025092119523427300_zwaf104-B19","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","article-title":"Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"2025092119523427300_zwaf104-B20","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1016\/j.jacc.2020.09.610","article-title":"VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-containing lipoproteins","volume":"76","author":"Balling","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025092119523427300_zwaf104-B21","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","article-title":"Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction","volume":"34","author":"Jorgensen","year":"2013","journal-title":"Eur Heart J"},{"key":"2025092119523427300_zwaf104-B22","doi-asserted-by":"crossref","first-page":"e002765","DOI":"10.1161\/JAHA.115.002765","article-title":"Remnant lipoprotein cholesterol and incident coronary heart disease: the Jackson heart and framingham offspring cohort studies","volume":"5","author":"Joshi","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2025092119523427300_zwaf104-B23","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1093\/eurheartj\/ehab293","article-title":"Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction","volume":"42","author":"Varbo","year":"2021","journal-title":"Eur Heart J"},{"key":"2025092119523427300_zwaf104-B24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1749-6632.1985.tb11860.x","article-title":"Lipoproteins of special significance in atherosclerosis. Insights provided by studies of type III hyperlipoproteinemia","volume":"454","author":"Mahley","year":"1985","journal-title":"Ann N Y Acad Sci"},{"key":"2025092119523427300_zwaf104-B25","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/MOL.0000000000000682","article-title":"Remnant lipoproteins: are they equal to or more atherogenic than LDL?","volume":"31","author":"Salinas","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"2025092119523427300_zwaf104-B26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41586-020-2338-1","article-title":"Repositioning of the global epicentre of non-optimal cholesterol","volume":"582","author":"Collaboration NCDRF","year":"2020","journal-title":"Nature"},{"key":"2025092119523427300_zwaf104-B27","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2022.12567","article-title":"Trends in lipid concentrations and lipid control among US adults, 2007\u20132018","volume":"328","author":"Aggarwal","year":"2022","journal-title":"JAMA"},{"key":"2025092119523427300_zwaf104-B28","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/eurjpc\/zwae102","article-title":"The role of remnant cholesterol in patients with ST-segment elevation myocardial infarction","volume":"31","author":"Zhou","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2025092119523427300_zwaf104-B29","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/eurheartj\/ehx097","article-title":"Acute coronary syndrome in women: rising hospitalizations in middle-aged French women, 2004\u201314","volume":"38","author":"Gabet","year":"2017","journal-title":"Eur Heart J"},{"key":"2025092119523427300_zwaf104-B30","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jacc.2024.05.070","article-title":"Prediction of cumulative exposure to atherogenic lipids during early adulthood","volume":"84","author":"Wilkins","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025092119523427300_zwaf104-B31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2025092119523427300_zwaf104-B32","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/joim.13059","article-title":"Contribution of remnant cholesterol to cardiovascular risk","volume":"288","author":"Langsted","year":"2020","journal-title":"J Intern Med"},{"key":"2025092119523427300_zwaf104-B33","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/eurjpc\/zwad064","article-title":"Complexity of triglyceride-rich lipoprotein remnant cholesterol with atherosclerotic cardiovascular disease risk","volume":"30","author":"Santos","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"2025092119523427300_zwaf104-B34","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCULATIONAHA.117.032318","article-title":"Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial","volume":"138","author":"Vallejo-Vaz","year":"2018","journal-title":"Circulation"},{"key":"2025092119523427300_zwaf104-B35","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with Type 2 diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"N Engl J Med"},{"key":"2025092119523427300_zwaf104-B36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrcardio.2018.3","article-title":"Advances in lipid-lowering therapy through gene-silencing technologies","volume":"15","author":"Nordestgaard","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2025092119523427300_zwaf104-B37","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N Engl J Med"},{"key":"2025092119523427300_zwaf104-B38","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N Engl J Med"},{"key":"2025092119523427300_zwaf104-B39","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/eurjpc\/zwae090","article-title":"Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial","volume":"31","author":"Zimerman","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2025092119523427300_zwaf104-B40","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/eurjpc\/zwad107","article-title":"Remnant cholesterol: a reliable prognostic marker?","volume":"31","author":"Pirillo","year":"2024","journal-title":"Eur J Prev Cardiol"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf104\/62170585\/zwaf104.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/32\/13\/1181\/62170585\/zwaf104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/32\/13\/1181\/62170585\/zwaf104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T23:52:40Z","timestamp":1758498760000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/32\/13\/1181\/8042690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":40,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,2,25]]},"published-print":{"date-parts":[[2025,9,22]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwaf104","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,2,25]]}}}